Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

N/ACompletedNCT01232062

Peking University Cancer Hospital & Institute46 enrolled

Overview

To access the effectiveness of High-dose Cyclophosphamide Combined Chemotherapy combined with adoptive cellular therapy with dentritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients

1. Metastatic breast cancer patients should be definitively diagnosis based on histopathology, with ER-negative and PR-negative, FISH testing for her-2-negative 2. All the patients enrolled will be given standard HDC and cellular therapy.HDC and cellular therapy consisting of one cycle of HDC followed by an apheresis and ex vivo cultures to generate DC and CIK. DC-CIK infusions were given to each patient, followed by two cycles HDC, plus low-dose Oral Cyclophosphamide. 3. PET-CT scans were done on each patients at baseline and after chemotherapy. The response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. 4. Estimate time to progression, survival rates and clinical benefit response on patients. 5. Find biomarkers associated with drug response.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Neoplasms Neoplasm Metastasis

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Failure to anthracycline and/or taxol chemotherapy; * metastatic tumor is histologically confirmed by immunohistochemical staining to be ER-negative and PR-negative. FISH testing for her-2-negative; * Metastatic tumor can not be removed through surgery procedure; * Metastatic tumor measured by PET-CT scan is at least 1cm; * An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * Normal cardiac, hepatic, renal and bone marrow functions; * Life expectancy ≥3 months. Exclusion Criteria: * Do not finish twice PET-CT scan; * Central nervous system metastases; * Serious or uncontrolled concurrent medical illness; * History of other malignancies; * Having been enrolled in some other clinal trials within a month;

Locations (1)

Beijing Cancer Hospital

Beijing, China

Outcomes

Primary Outcomes

response to chemotherapy

Response to chemotherapy is evaluated by Response Evaluation Criteria in Solid Tumors(RESIST).

Time frame: 4months

Secondary Outcomes

Time to disease progression

Time to disease progression is measured from the date therapy is initiated to the date of documented disease progression.

Time frame: six months to one year

survival rates

Time frame: one-year

clinical benefit response

clinical benefit response include CR,PR,SD

Time frame: six months to one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.